Scholarlink

Background <p>Inadequate selectivity, toxicity, high costs, low bioavailability, and susceptibility to drug resistance are all therapeutic limitations associated with resistant breast cancer treatments. Therefore, the present challenge is to develop highly effective anti-breast cancer targets. Within this context, the current study aims to develop amino acid-based cholesteryl ester complexes (AACE) for targeting triple-negative breast cancer cells (MDA-MB-231).</p> Results <p>The results of in vitro cytotoxicity for AACE (PHC, PRC, VAC) complexes on triple-negative breast carcinoma (MDA-MB-231), lung cancer (A549), and normal breast cells (MCF-10A) revealed significant potency and selectivity against MDA-MB-231 cells (IC<sub>50</sub> PHC = 32.58&#xa0;μM, PRC = 42.76&#xa0;μM, VAC = 59.23&#xa0;μM) and good cytocompatibility over normal breast cells (MCF-10A) compared to erlotinib. All of the complexes demonstrated a lower cytotoxic impact on A549 cells (lung cancer) compared to erlotinib. The most cytotoxic complex, PHC, showed good DNA cleavage ability. Moreover, PHC and PRC complexes, along with erlotinib, showed hemocompatibility in the concentration range of 3.125-50&#xa0;μM but revealed mild hemolytic toxicity at high concentrations (100&#xa0;μM). Molecular docking analysis (3EQM-PHC = -9.16, 3EQM-PRC = − 9.55&#xa0;kcal/mol; 1M17-PHC = − 8.39, 1M17-PRC = − 8.84&#xa0;kcal/mol) revealed strong binding interactions of aromatase and EGFR proteins with all the complexes. Additionally, DFT studies showed a good correlation between ∆E values (PHC = 5.811&#xa0;eV, PRC = 6.2563&#xa0;eV), suggesting the good bioactivity of PHC. All complexes showed compliance with drug-likeness and ADMET requirements.</p> Conclusions <p>The results of cytotoxicity (MDA-MB-231), biocompatibility (MCF-10A), DNA cleavage, in vitro hemolysis, DFT, molecular docking, and ADMET evaluations indicate the significant potential of PHC as a possible target for resistant breast cancer cells (MDA-MB-231).</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In-vitro and in-silico screening of amino acid based-cholesteryl esters: comparative investigation to explore possible triple-negative breast cancer targets

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月12日

查看全文
  • Mayuresh Shinde,
  • Rishikesh Parulekar,
  • Neela Bhatia,
  • Shitalkumar Patil,
  • Kailas Sonawane,
  • Manish Bhatia

摘要

Background

Inadequate selectivity, toxicity, high costs, low bioavailability, and susceptibility to drug resistance are all therapeutic limitations associated with resistant breast cancer treatments. Therefore, the present challenge is to develop highly effective anti-breast cancer targets. Within this context, the current study aims to develop amino acid-based cholesteryl ester complexes (AACE) for targeting triple-negative breast cancer cells (MDA-MB-231).

Results

The results of in vitro cytotoxicity for AACE (PHC, PRC, VAC) complexes on triple-negative breast carcinoma (MDA-MB-231), lung cancer (A549), and normal breast cells (MCF-10A) revealed significant potency and selectivity against MDA-MB-231 cells (IC50 PHC = 32.58 μM, PRC = 42.76 μM, VAC = 59.23 μM) and good cytocompatibility over normal breast cells (MCF-10A) compared to erlotinib. All of the complexes demonstrated a lower cytotoxic impact on A549 cells (lung cancer) compared to erlotinib. The most cytotoxic complex, PHC, showed good DNA cleavage ability. Moreover, PHC and PRC complexes, along with erlotinib, showed hemocompatibility in the concentration range of 3.125-50 μM but revealed mild hemolytic toxicity at high concentrations (100 μM). Molecular docking analysis (3EQM-PHC = -9.16, 3EQM-PRC = − 9.55 kcal/mol; 1M17-PHC = − 8.39, 1M17-PRC = − 8.84 kcal/mol) revealed strong binding interactions of aromatase and EGFR proteins with all the complexes. Additionally, DFT studies showed a good correlation between ∆E values (PHC = 5.811 eV, PRC = 6.2563 eV), suggesting the good bioactivity of PHC. All complexes showed compliance with drug-likeness and ADMET requirements.

Conclusions

The results of cytotoxicity (MDA-MB-231), biocompatibility (MCF-10A), DNA cleavage, in vitro hemolysis, DFT, molecular docking, and ADMET evaluations indicate the significant potential of PHC as a possible target for resistant breast cancer cells (MDA-MB-231).

Graphical Abstract